Department of Clinical Pharmacy, School of Pharmacy, University of Gondar, Gondar, Ethiopia.
Division of Pharmacy, School of Allied Health, University of Western Australia, Perth, WA, Australia.
Qual Life Res. 2023 Nov;32(11):3269-3277. doi: 10.1007/s11136-023-03473-3. Epub 2023 Jul 5.
The aim of this study was to investigate treatment burden and its relationship with health-related quality of life (HRQoL) among patients with multimorbidity (two or more chronic diseases) who were taking prescription medications and attending the outpatient department of the University of Gondar Comprehensive Specialized Teaching Hospital.
A cross-sectional study was conducted between March 2019 and July 2019. Treatment burden was measured using the Multimorbidity Treatment Burden Questionnaire (MTBQ), while HRQoL was captured using the Euroqol-5-dimensions-5-Levels (EQ-5D-5L).
A total of 423 patients participated in the study. The mean global MTBQ, EQ-5D index, and EQ-VAS scores were 39.35 (± 22.16), 0.83 (± 0.20), and 67.32 (± 18.51), respectively. Significant differences were observed in the mean EQ-5D-Index (F [2, 81.88] 33.1) and EQ-VAS (visual analogue scale) scores (F [2, 75.48] = 72.87) among the treatment burden groups. Follow up post-hoc analyses demonstrated significant mean differences in EQ-VAS scores across the treatment burden groups and in EQ-5D index between the no/low treatment burden and high treatment burden, as well as between the medium treatment burden and high treatment burden. In the multivariate linear regression model, every one SD increase in the global MTBQ score (i.e., 22.16) was associated with a decline of 0.08 in the EQ-5D index (β - 0.38, 95%CI - 0.48, - 0.28), as well as a reduction of 9.4 in the EQ-VAS score (β - 0.51, 95%CI -0.60, - 0.42).
Treatment burden was inversely associated with HRQoL. Health care providers should be conscious in balancing treatment exposure with patients' HRQoL.
本研究旨在调查在服用处方药并到贡德尔大学综合专业教学医院门诊部就诊的患有多种疾病（两种或多种慢性疾病）的患者中，治疗负担及其与健康相关的生活质量（HRQoL）之间的关系。
本研究为横断面研究，于 2019 年 3 月至 2019 年 7 月进行。使用多疾病治疗负担问卷（MTBQ）测量治疗负担，使用欧洲五维健康量表（EQ-5D-5L）测量 HRQoL。
共有 423 名患者参加了这项研究。全球 MTBQ、EQ-5D 指数和 EQ-VAS 评分的平均值分别为 39.35（±22.16）、0.83（±0.20）和 67.32（±18.51）。在治疗负担组中，EQ-5D 指数（F[2,81.88]33.1）和 EQ-VAS（视觉模拟量表）评分（F[2,75.48]72.87）存在显著差异。随访事后分析显示，治疗负担组之间的 EQ-VAS 评分存在显著的均值差异，以及在无/低治疗负担与高治疗负担之间、中治疗负担与高治疗负担之间的 EQ-5D 指数差异。在多变量线性回归模型中，全球 MTBQ 评分每增加一个标准差（即 22.16），EQ-5D 指数就会下降 0.08（β-0.38，95%CI-0.48，-0.28），EQ-VAS 评分下降 9.4（β-0.51，95%CI-0.60，-0.42）。
治疗负担与 HRQoL 呈负相关。医疗保健提供者应注意在平衡治疗暴露与患者的 HRQoL 之间的关系。
